• 1. Ester-directed orthogonal dual C–H activation and ortho aryl C–H alkenylation via distal weak coordination?
  Manickam Bakthadoss,Tadiparthi Thirupathi Reddy,Vishal Agarwal,Duddu S. Sharada Chem. Commun., 2022,58, 1406-1409
• 2. Dissociation of large gaseous serine clusters produces abundant protonated serine octamer
  Jacob S. Jordan,Evan R. Williams Analyst, 2021,146, 2617-2625
• 3. Exciton manipulation in rippled transition metal dichalcogenides?
  Chen Long,Ying Dai,Jianwei Li,Hao Jin Nanoscale, 2020,12, 21124-21130
• 4. Dissolved oxygen sensor based on fluorescence quenching of oxygen-sensitive ruthenium complexes immobilized in sol–gel-derived porous silica coatings
  Analyst, 1996,121, 785-788
• 5. Fe3O4 nanoparticle chains with N-doped carbon coating: magnetotactic bacteria assisted synthesis and high-rate lithium storage?
  Dan Yang,Yanping Zhou,Xianhong Rui,Jixin Zhu,Ziyang Lu,Eileen Fong,Qingyu Yan RSC Adv., 2013,3, 14960-14962

Recent Advances in the Study of 6-(Difluoromethoxy)-3-fluoro-pyridine-2-carbonitrile (CAS: 1949836-84-3)

The compound 6-(Difluoromethoxy)-3-fluoro-pyridine-2-carbonitrile (CAS: 1949836-84-3) has recently garnered significant attention in the field of chemical biology and pharmaceutical research. This heterocyclic compound, characterized by its difluoromethoxy and fluoro substituents, has shown promising potential in various therapeutic applications. Recent studies have focused on its synthesis, pharmacological properties, and potential as a key intermediate in drug development.

One of the primary areas of interest is the compound's role as a building block in the synthesis of novel kinase inhibitors. Kinases are critical targets in cancer therapy, and the unique electronic properties of 6-(Difluoromethoxy)-3-fluoro-pyridine-2-carbonitrile make it an attractive candidate for modulating kinase activity. Recent publications have highlighted its use in the development of selective inhibitors for tyrosine kinases, which are implicated in numerous oncogenic pathways.

In addition to its applications in oncology, this compound has also been investigated for its potential in treating inflammatory and autoimmune diseases. Researchers have explored its ability to interact with key signaling molecules in the immune system, such as JAK-STAT pathways. Preliminary results suggest that derivatives of 6-(Difluoromethoxy)-3-fluoro-pyridine-2-carbonitrile exhibit potent anti-inflammatory effects in vitro and in vivo, making them promising candidates for further preclinical development.

The synthesis of 6-(Difluoromethoxy)-3-fluoro-pyridine-2-carbonitrile has also been a focal point of recent research. Advances in fluorination techniques and catalytic methods have enabled more efficient and scalable production of this compound. Notably, a 2023 study published in the Journal of Medicinal Chemistry demonstrated a novel one-pot synthesis approach that significantly improves yield and reduces production costs, which could facilitate its broader use in pharmaceutical manufacturing.

Despite these promising developments, challenges remain in optimizing the pharmacokinetic and safety profiles of derivatives based on this scaffold. Ongoing research aims to address these issues through structural modifications and formulation strategies. For instance, recent work has explored the incorporation of prodrug moieties to enhance bioavailability and reduce off-target effects.

In conclusion, 6-(Difluoromethoxy)-3-fluoro-pyridine-2-carbonitrile (CAS: 1949836-84-3) represents a versatile and valuable scaffold in modern drug discovery. Its applications span multiple therapeutic areas, and ongoing research continues to uncover new opportunities for its use. As synthetic methodologies advance and our understanding of its biological interactions deepens, this compound is poised to play an increasingly important role in the development of next-generation therapeutics.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)